Pestalozzi advises Norcliffe Capital in connection with investment in Santersus

On 1 December 2025, it has been announced that Santersus AG, a Switzerland-based innovative therapeutic aphresis company, completed a Series A financing round, led by Norcliffe Capital, a UK based Life Sciences investment manager, with participation from Terumo Ventures. The financing will support the advancement of Santersus' NucleoCapture™ into pivotal clinical development while accelerating progress across Santersus’ broader pipeline.

In addition, Santersus has entered a strategic collaboration with Terumo Blood and Cell Technologies to advance NucleoCapture™ for the treatment of sepsis, a disease that kills 11M people worldwide each year. 

Pestalozzi advised Norcliffe Capital on matters of Swiss law in connection with the Series A financing, alongside Burness Paull.

Pestalozzi Attorneys at Law Ltd.
Zurich – Feldeggstrasse 4 | 8008 Zurich | Switzerland | T +41 44 217 91 11
Geneva – Cours de Rive 13 | 1204 Geneva | Switzerland | T +41 22 999 96 00
www.pestalozzilaw.com